Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.
"Authorized generics are a very effective sales strategy for Aton Pharma's product portfolio," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "We are extremely pleased with the successful launch of the authorized generic for Timoptic-XE and we are now highly confident in our ability to execute this type of program for other Aton products when the opportunity arises."